LeroyMonroeParkerMD

PubMed

• 13 citations
  Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
  Erica L. Mayer, Adrienne B. Gropper, Lyndsay Harris, J. Gold, Leroy M. Parker, Irene Kuter, Steven E. Come, Julie Najita, Hao Guo, Eric P. Winer, Harold J. Burstein> ;Clinical Breast Cancer. 2015 Feb 1
• 73 citations
  A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes
  Wendy Y. Chen, Anita Giobbie-Hurder, Kathryn Gantman, Jennifer Savoie, Rochelle Scheib, Leroy M. Parker, Eva S. Schernhammer> ;Breast Cancer Research and Treatment. 2014 Apr 10
• 30 citations
  A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers
  Eva S. Schernhammer, Anita Giobbie-Hurder, K. Gantman, Jennifer Savoie, Rochelle Scheib, Leroy M. Parker, Wendy Y. Chen> ;Cancer Causes & Control. 2012 Feb 28
• Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study.
  Berek JS, Edwards RP, Parker L, DeMars LR, Herzog TJ, Lentz SS, Morris R, Akerley WL, Holloway RW, Method M, Plaxe SC, Walker JL, Schindler T, Schulze E, Krasner CN> ;J. Clin. Oncol.. 2011-05-20
• 4 citations
  Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
  Susana M. Campos, Suzanne Berlin, Leroy M. Parker, Wendy Y. Chen, Craig A. Bunnell, T. Atkinson, Julie Lee, Ursula A. Matulonis, Michelle S. Hirsch, Lyndsay Harris, Ca...> ;International Journal of Clinical Oncology. 2010 Apr 20
• 51 citations
  Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine
  Brian D. Snyder, Marsha A Cordio, Ara Nazarian, S. Daniel Kwak, David J Chang, Vahid Entezari, David Zurakowski, Leroy M. Parker> ;Clinical Cancer Research. 2009 Dec 15
• 16 citations
  Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type.
  Katherine S. Upchurch, Leroy M. Parker, Robert E. Scully, Stephen M. Krane> ;Journal of Bone and Mineral Research. 2009 Dec 3
• Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer.
  Come SE, Parker LM, Wulf G, Kuter I, Ryan PD, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer EP> ;J. Clin. Oncol.. 2009-05-20
• 109 citations
  VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
  Harold J. Burstein, Yi Chen, Leroy M. Parker, Jennifer Savoie, Jerry Younger, Irene Kuter, Paula D. Ryan, Judy Garber, Helen H.W. Chen, Susana M. Campos, Lawrence N. S...> ;Clinical Cancer Research. 2008 Dec 1
• 1034 citations
  Molecular Definition of Breast Tumor Heterogeneity
  Michail Shipitsin, Lauren L. Campbell, Pedram Argani, Stanislawa Weremowicz, Noga Bloushtain-Qimron, Jun Yao, Tatiana Nikolskaya, Tatiana Serebryiskaya, Rameen Beroukh...> ;Cancer Cell. 2007 Mar 13
• 21 citations
  Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
  Nan Lin, Leroy M. Parker, Steven E. Come, Harold J. Burstein, Margaret Haldoupis, N. Ryabin, Rebecca Gelman, Eric P. Winer, Lawrence N. Shulman> ;Investigational New Drugs. 2007 Mar 8
• Control of acute toxicity with amifostine and pelvic chemoradiotherapy.
  Tate M, Wilson L, Silverman C, Helm W, Parker L, Metzinger D, Paris K, Carrascosa L, Yashar C> ;J. Clin. Oncol.. 2006-06-20
• Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
  Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN> ;J. Clin. Oncol.. 2006-06-20
• 35 citations
  Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
  Harold J. Burstein, Jennifer R. Bellon, Sharon Galper, Hsiao-Ming Lu, Irene Kuter, Alphonse G. Taghian, Julia Wong, Rebecca Gelman, Craig A. Bunnell, Leroy M. Parker, ...> ;International Journal of Radiation Oncology, Biology, Physics. 2006 Feb 1
• 58 citations
  Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy
  Harold J. Burstein, Leroy M. Parker, Aparna Keshaviah, Jennifer A. Doherty, Ann H. Partridge, Lidia Schapira, Paula D. Ryan, Jerry Younger, Lyndsay Harris, Beverly Moy...> ;Journal of Clinical Oncology. 2005 Nov 20
• 5 citations
  Palliative radiofrequency ablation of a fungating, symptomatic breast lesion.
  Eric vanSonnenberg, Sridhar Shankar, Leroy M. Parker, Lawrence Cheung, Paul R. Morrison, Stuart G. Silverman, Dirk Igelhart> ;AJR. American Journal of Roentgenology. 2005 Mar 1
• 61 citations
  Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
  John F.R. Robertson, Bjorn Erikstein, Kent Osborne, John Pippen, Steven E. Come, Leroy M. Parker, Stan Gertler, Mike P. Harrison, David A Clarke> ;Clinical Pharmacokinetics. 2004 Jan 1
• 15 citations
  Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
  Martine Piccart, Leroy M. Parker, Kathleen I. Pritchard> ;Annals of Oncology. 2003 Jul 1
• 211 citations
  Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer...
  Harold J. Burstein, Lyndsay Harris, Rebecca Gelman, Susan C. Lester, Raquel A. Nunes, Carolyn M. Kaelin, Leroy M. Parker, Leif W. Ellisen, Irene Kuter, Michele A. Gadd...> ;Journal of Clinical Oncology. 2003 Jan 1
• 450 citations
  Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressin...
  CK Osborne, J. Pippen, S.E. Jones, Leroy M. Parker, M. Ellis, Steven E. Come, Stan Gertler, J.T. May, Gary V. Burton, I. Dimery, A. Webster, C. Morris, Richard M. Elle...> ;Journal of Clinical Oncology. 2002 Aug 15
• 26 citations
  The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results.
  C T Griffiths, Leroy M. Parker, Sunyoung Lee, N J Finkler> ;International Journal of Gynecological Cancer. 2002 Jul 1
• Fulvestrant: Clinical application of an estrogen receptor downregulator
  Michael H. Torosian, Joyce A. O'Shaughnessy, Leroy M. Parker, Charles Vogel> ;Clinical Therapeutics. 2002 Jan 1
• 3 citations
  Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
  Leroy M. Parker> ;Clinical Therapeutics. 2002 Jan 1
• 271 citations
  Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer
  Harold J. Burstein, Irene Kuter, Susana M. Campos, Rebecca Gelman, Laura Tribou, Leroy M. Parker, Judith Manola, Jerry Younger, Ursula A. Matulonis, Craig A. Bunnell, ...> ;Journal of Clinical Oncology. 2001 May 15
• 217 citations
  Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
  Harold J. Burstein, Judith Manola, Jerry Younger, Leroy M. Parker, Craig A. Bunnell, Rochelle Scheib, Ursula A. Matulonis, Judy Garber, Kathryn Clarke, Lawrence N. Shu...> ;Journal of Clinical Oncology. 2000 Mar 13
• Join now to see all